Immunotherapy with anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PDL-1) agents may facilitate the progression to severe COVID-19 in asymptomatic SARS-CoV-2 patients according to the so-called “cytokine storm” theory (16). The gene discussed is CD274; the disease is COVID-19.